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Abstract
Hospitalization of the elderly for invasive pneumococcal disease is frequently accompanied by the occurrence of an adverse
cardiac event; these are primarily new or worsened heart failure and cardiac arrhythmia. Herein, we describe previously
unrecognized microscopic lesions (microlesions) formed within the myocardium of mice, rhesus macaques, and humans
during bacteremic Streptococcus pneumoniae infection. In mice, invasive pneumococcal disease (IPD) severity correlated
with levels of serum troponin, a marker for cardiac damage, the development of aberrant cardiac electrophysiology, and the
number and size of cardiac microlesions. Microlesions were prominent in the ventricles, vacuolar in appearance with
extracellular pneumococci, and remarkable due to the absence of infiltrating immune cells. The pore-forming toxin
pneumolysin was required for microlesion formation but Interleukin-1b was not detected at the microlesion site ruling out
pneumolysin-mediated pyroptosis as a cause of cell death. Antibiotic treatment resulted in maturing of the lesions over one
week with robust immune cell infiltration and collagen deposition suggestive of long-term cardiac scarring. Bacterial
translocation into the heart tissue required the pneumococcal adhesin CbpA and the host ligands Laminin receptor (LR) and
Platelet-activating factor receptor. Immunization of mice with a fusion construct of CbpA or the LR binding domain of CbpA
with the pneumolysin toxoid L460D protected against microlesion formation. We conclude that microlesion formation may
contribute to the acute and long-term adverse cardiac events seen in humans with IPD.
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pooled incidence rate for cardiac complications during hospitalization for CAP is approximately 18% [1]. Risk for cardiac
complications is greatest immediately following the diagnosis of
pneumonia; with approximately 90% of cardiac events occurring
within the first 7 days and .50% occurring within the first 24 h
[2,3]. In one study by Corrales-Medina et al. of cardiac

Introduction
Severe community-acquired pneumonia (CAP) carries an
extensively documented risk for adverse cardiac events such as
congestive heart failure, arrhythmias, and myocardial infarction. A
meta-analysis of 19 observational studies determined that the
PLOS Pathogens | www.plospathogens.org
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innate immune responses to a range of bacterial components can
alter cardiac function transiently but do not appear to induce
death of cardiomyocytes or explain the persistence of cardiac
dysfunction following acute disease.
As the leading cause of bacterial meningitis [11], the hostpathogen interactions for S. pneumoniae occurring at the blood
brain barrier have been extensively studied. It is known that
bacterial translocation across cerebral vascular endothelial cells is
dependent on the binding of the bacterial adhesin Choline binding
protein A (CbpA) to endothelial cell Laminin receptor (LR)
followed by ligation of phosphorylcholine (ChoP) on the bacterial
cell wall to PAFR [12,13]. These interactions result in the uptake
of the bacteria in vesicles and their transport to the basolateral
surface of the cell so as to translocate bacteria from the blood into
the brain. In the lungs and central nervous system, host cell
damage is mediated by pneumolysin, a thiol-activated cholesterol
dependent pore-forming toxin that is cytolytic at high concentrations but induces apoptosis at low concentrations [14,15].
Additional tissue damage may occur as a result of TLR-2
activation by pneumococcal cell wall, which results in profuse
cytokine production, immune cell infiltration, and in some
instances cell death [10,16,17].
Herein, we explored the possibility that S. pneumoniae directly
damages the heart during invasive pneumococcal disease (IPD)
and this contributes towards the occurrence of an adverse cardiac
event. We describe the novel observation of non-purulent
microscopic lesions (i.e. microlesion) filled with pneumococci
within the myocardium and describe the molecular basis for S.
pneumoniae invasion of cardiac tissue and cardiomyocyte cell
death within the lesion. Our findings suggest a previously
unrecognized pathological aspect of pneumococcal infection that
may help to explain the greater incidence of adverse cardiac events
in adults with severe IPD and is potentially vaccine preventable.
Decreasing the morbidity and mortality associated with pneumococcal CAP in the aged is particularly critical, as by 2050, 20% of
the world population will be .65 years old and as such highly
susceptible to CAP and IPD [18].

Author Summary
Hospitalization for community-acquired pneumonia carries
a documented risk for adverse cardiac events. These occur
during infection and contribute to elevated mortality rates
in convalescent individuals up to 1 year thereafter. We
describe a previously unrecognized pathogenic mechanism by which Streptococcus pneumoniae, the leading
cause of community-acquired pneumonia, causes direct
cardiotoxicity and forms microscopic bacteria-filled lesions
within the heart. Microlesions were detected in experimentally infected mice and rhesus macaques, as well as in
heart sections from humans who succumbed to invasive
pneumococcal disease (IPD). Cardiac microlesion formation required interaction of the bacterial adhesin CbpA
with host Laminin receptor and bacterial cell wall with
Platelet-activating factor receptor. Microlesion formation
also required the pore-forming toxin pneumolysin. When
infected mice were rescued with antibiotics, we observed
robust signs of collagen deposition at former lesion sites.
Thus, microlesions and the scarring that occurs thereafter
may explain why adverse cardiac events occur during and
following IPD.

complications during pneumonia, congestive heart failure occurred in 21%, arrhythmias occurred in 10%, and myocardial
infarction occurred in 3% of hospitalized adults. In contrast, these
distinct complications occurred in only 1.4%, 1.0% and 0.1% of
outpatients, respectively, indicating that disease severity at time of
hospital presentation is a significant risk factor. Cardiac complications were implicated as a direct or underlying cause of death in
27% of the pneumonia-associated deaths. Furthermore, death
within 30 days of pneumonia onset was up to five times greater in
patients who experienced an adverse cardiac event than among
those who did not [2]. Importantly, elevated mortality risk in
individuals with CAP persists long-after disease resolution. Kaplan
et al. demonstrated that the 1-year mortality rate in CAPconvalescent individuals to be 2.69-fold higher than that of the
general population and 1.93-fold higher than individuals hospitalized for all other reasons [4]. Streptococcus pneumoniae (the
pneumococcus), is the most common cause of CAP and sepsis [5],
and has been directly associated with an adverse cardiac event in
19.4% of 170 admitted adult patients [6]. Thus, adverse cardiac
events contribute in a significant fashion to the overall morbidity
and mortality that is associated with adult bacterial pneumonia.
This includes during pneumococcal infection, the most prevalent
setting for CAP.
Acute bacterial pneumonia stresses the heart by increasing
myocardial oxygen demand at a time when oxygenation is
compromised by ventilation-perfusion mismatch. Pneumonia and
the resulting invasive bacterial disease also raise circulating levels
of pro-inflammatory cytokines, which promote thrombogenesis
and suppress ventricular function [7]. Notably, engagement of
Toll-like receptors (TLR)-2, TLR-4 and TLR-5 on cardiomyocytes by Staphylococcus aureus peptidoglycan, E. coli lipopolysaccharide, and Salmonella typhimurium flagellin, respectively, has
been shown to result in decreased cardiomyocyte contractility [8].
However, studies with flagellin demonstrated that TLR engagement did not induce myocardial cell death in vivo and that these
negative effects on contractility were reversible [9]. Pneumococcal
cell wall has been shown to enter cardiomyocytes in a Plateletactivating factor receptor (PAFR) dependent and TLR-2 independent manner and negatively impact contractility of intact
mouse and rat hearts without death of cardiomyocytes [10]. Thus,
PLOS Pathogens | www.plospathogens.org

Results
IPD is associated with myocardial damage and alterations
in cardiac electrophysiology
Challenge of BALB/c mice with S. pneumoniae strain TIGR4
via the intraperitoneal route resulted in a linear increase in
bacterial burden in blood from 12 h to 30 h post-infection and led
to severe IPD (Fig. 1A). To test if myocardial tissue damage was
incurred during IPD, serum samples collected at various time
points were tested for cardiac troponin as a function of the density
of S. pneumoniae in the blood. A significant positive correlation
was observed between bacterial titers and this clinical marker of
cardiac injury (Fig. 1B). To assess whether alterations in cardiac
electrophysiology accompanied cardiac injury, we performed
limb-lead ECG analysis prior to and during experimental
infection. All infected mice showed initial compensatory alterations, followed by progressive aberrant changes in cardiac
electrophysiology (Fig. 1C, Fig. S1). Uninfected control mice
had normal cardiac electrophysiology despite repeated exposure to
anesthesia through 48 h (Fig. S1). Electrophysiological abnormalities observed during infection included a compensatory
increased and then reduced R wave indicating stronger and then
weaker contractions, the development of a bifurcated P-wave and
prolonged PQ and PR interval indicating disruption of the
conduction path from the sino-atrial node and suggestive of
multifocal atrial rhythms, and the chaotic conduction of electrical
2
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Figure 1. IPD is associated with alterations in cardiac electrophysiology and heart damage. A) Bacterial titers in blood of mice at 12
(n = 24), 24 (n = 17), and 30 (n = 11) h following intraperitoneal challenge with 103 CFU of S. pneumoniae, strain TIGR4. *P,0.05 by two-tailed
Student’s t-test. B) Regression analysis of blood bacterial titers and cardiac troponin-I concentrations at various time points following intraperitoneal
challenge with TIGR4 (n = 16). Statistical analysis was done using a Pearson correlation coefficient calculator. C) Limb-lead electrocardiogram (ECG)
tracings from a single mouse prior to and following intraperitoneal infection at 0, 12, 24 and 30 h. Letters at 0 h identify the corresponding ECG
waves. D) ECG tracings obtained from 3 representative mice (Mouse [M] 2–4) 24–30 h post infection highlighting the variety of arrhythmias observed
among the infected mice (n = 8 for 0, 12, and 24 h; n = 6 for 30 h). The ECGs of control saline treated mice showed no electrical disturbances despite
repeated anesthesia and ECG measurement (n = 2; see Fig. S1). Note in panels C and D the pronounced bifurcated P-wave (blue dot), the early
compensatory increase and then reduced R wave at late time points (purple dot), the presence of a J-wave (orange dot), the elongated intervals for
contraction (red dot), PQ wave (black dot) and fibrillation (green dot). ECG tracings were acquired at 200 kHz using the 100B electrocardiogram data
acquisition system (iWorx) with mice under isoflurane anesthesia. Fig. S1 shows an extended ECG rhythm strip for these infected mice.
doi:10.1371/journal.ppat.1004383.g001

(SIV)-infected rhesus macaques that had succumbed to experimental serotype 19F pneumococcal pneumonia [20]. In these
primate experiments, 3 of 23 macaques succumbed to IPD within
one week of infection, despite antimicrobial therapy, and all 3 of
these animals had cardiac lesions similar in size and with vacuolar
morphology. They were distinct from those seen in the mice due to
the absence of visible pneumococci (Fig. 2J). Two animals that
were infected with S. pneumoniae, but did not develop fulminate
disease, were taken to necropsy one month after bacterial
challenge due to evidence of progressive SIV disease. Cardiac
lesions similar to those in macaques that died as a result of IPD
were not seen in these two animals.

signals indicative of a damaged conduction system (Fig. 1C–D).
Of note, considerable variability in regards to the specific
electrophysiological abnormality observed for each mouse was
observed (Fig. 1D, Fig. S1).

Cardiac microlesions form as the result of IPD
When the hearts from BALB/c mice with IPD were examined
for pathology, we observed the presence of microscopic lesions
(microlesions) randomly distributed throughout the ventricular
myocardium (Fig. 2A). These were distinct from myocarditis and
pericarditis that were also occasionally observed (Fig. 2B). In
many instances, IPD microlesions were adjacent to cardiac blood
vessels suggesting cardiac tissue invasion might have arisen by
penetration or migration of the bacteria through the vascular
endothelium (Fig. 2C). Lesions were characterized by the
expansion of the interstitium between cardiomyocytes, extracellular vacuolation, the apparent loss of cardiomyocytes, and the stark
absence of infiltrating immune cells within the lesion and
surrounding tissue (Fig. 2C–F). IPD microlesions were highly
distinct from the purulent cardiac abscesses that develop when
mice are infected with Staphylococcus aureus (Fig. 2G) [19]; in
particular being considerably smaller in size and lacking the
prolific infiltration of immune cells. Using high power light
microscopy (Fig. 2F) and transmission electron microscopy
(Fig. 2H), bacteria with diplococcal morphology could be seen
within microlesions. Of note, although some diplococci were
detected within dying cardiomyocytes immediately adjacent to the
lesions, the bulk of bacteria were extracellular (Fig. 2F).
Immunofluorescent imaging using anti-capsular antibody was
confirmatory for S. pneumoniae (Fig. 2I). Microlesions were not
detected prior to 24 h following intraperitoneal infection and the
number and size of microlesions dramatically increased between
24 h to 30 h (Fig. 2D–E, Fig. 3A) when mice had ,106–7 and
.108 CFU/mL in their blood, respectively.
Cardiac microlesion formation also was observed in C57BL/6
mice infected with TIGR4 (Fig. 3B), as well as in BALB/c mice
infected with serotype 2 strain D39. For D39, the number of
microlesions observed at 30 h (2.3460.41 lesions/cardiac section;
n = 3) was lower than TIGR4 (39.369.9 lesions/cardiac section;
n = 8, Fig. 3A). This may be due to speed that the mice succumbed
to D39 infection (only 3 of 9 infected mice survived to 29 h),
precluding sufficient time for the microlesions to develop. Importantly, mice infected with TIGR4 via the intratracheal route also
developed cardiac microlesions (6.663.1 lesions per cardiac section;
n = 5). Thus, lesion formation occurred as a result of severe disease
and was not restricted by the challenge route. In mice infected with
TIGR4, microlesions were not detected in the infected kidneys,
livers, or spleens (n = 12). We did however detect a single
microlesion in a mouse gastrocnemius muscle at 30 h. Of note,
this lesion also lacked the infiltration of immune cells (Fig. S2).
To determine if lesions formed in non-human primates, we
examined cardiac sections from 3 simian immunodeficiency virus
PLOS Pathogens | www.plospathogens.org

Evidence of cardiac damage during IPD in humans
We also examined cardiac sections from 9 adults who had
succumbed to IPD despite critical care intervention. In heart
sections from 2 individuals, vacuolar lesions were observed
(Fig. 2K). Similar to the experimentally infected macaques that
had died of IPD, these lesions also did not contain pneumococci.
To determine if the absence of pneumococci in the rhesus
macaque and human cardiac lesions was due to the antimicrobial
therapy received during critical care, we infected mice with S.
pneumoniae and intervened 30 h post-infection with high-dose
ampicillin therapy. As early as 12 h after administering the
antibiotic, we observed cardiac microlesions that were now largely
devoid of bacteria yet maintained their vacuolar appearance
(Fig. 2L).

Microlesion formation is dependent on host LR and PAFr
and the bacterial adhesin CbpA
S. pneumoniae translocation across the vascular endothelium
requires at least two interactions: the adhesin CbpA binds to host
LR and cell wall ChoP binds to host PAFR [12,21]. Using CbpA
deficient pneumococci and PAFR2/2 mice, we observed a
requirement for these two proteins in cardiac microlesion
formation in BALB/c (Fig. 3A) and C57BL/6 (Fig. 3B) mice,
respectively. In addition to serving as an adhesin, CbpA binds to
serum Factor H and inhibits complement deposition [22]. Thus,
bacterial titers in mice infected with CbpA deficient pneumococci
were lower than the WT controls, as expected (Fig. 3A). To
address the possibility that reduced microlesion formation was due
to this lower bacterial load, mice were passively immunized with
monoclonal antibody against LR prior to TIGR4 intraperitoneal
infection. Antibodies against LR completely blocked cardiac
microlesion formation without negatively affecting levels of
pneumococci in the blood (Fig. 3C). Likewise, no differences in
bacterial titers in blood were seen in the PAFR2/2 mice infected
with TIGR4 versus WT mice (Fig. 3B). Thus, disruption of
CbpA/LR and ChoP/PAFR interactions in vivo inhibited cardiac
microlesion formation.
Using immunofluorescent microscopy, we subsequently determined that LR and PAFR were robustly expressed by endothelial
4
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Figure 2. Cardiac lesions form as the result of IPD. H&E stained cross section of a heart obtained from a BALB/c mouse 30 h postintraperitoneal challenge with TIGR4. A) Cardiac microlesions were randomly distributed throughout the mouse myocardium. The circled regions
demarcate lesion areas. B) Pericarditis was observed in rare mice at 30 h post infection. C) Cardiac microlesions were often observed to be adjacent
to blood vessels. D&E) Representative images of cardiac microlesions seen at 24 h (n = 8) and 30 h (n = 11) post infection, respectively. F) Higher
powered magnification of the 30 h cardiac microlesion shows S. pneumoniae bacterial aggregates within the microlesion. G) As a point of contrast, in
mice infected i.p. with Staphylococcus aureus (Sa) abscesses were large and characterized by a robust neutrophil response (white arrow). Tissue

PLOS Pathogens | www.plospathogens.org
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sample a gift from Dr. Eric Skaar, Nashville, TN. H) Transmission electron microscopy image of cardiac lesion indicates that the bacteria within have
diplococcal morphology. I) Immunofluorescent detection of the bacterial capsule (serotype 4) confirmed that the granular bodies are S. pneumoniae.
J) Representative cardiac lesion seen in the heart of 3 SIV-infected macaques that had succumbed to experimental pneumococcal challenge despite
antimicrobial therapy. Similar lesions were absent in the hearts of macaques that cleared the infection (n = 2). K) Cardiac lesion detected in heart of a
human adult that had succumbed to IPD. Lesions were observed in 2 of 9 human heart samples. L) Cardiac microlesion from a mouse with IPD that
had been treated with ampicillin beginning at 30 h post-infection. Cardiac section was collected 12 hours after initiating antimicrobial therapy (n = 4).
doi:10.1371/journal.ppat.1004383.g002

cells of vessels throughout the heart but were nearly absent in
cardiomyocytes (Fig. 3D). This observation was consistent with
the low permissiveness of HL-1 cardiomyocytes for pneumococcal
invasion in vitro in comparison to RBCEC6 rat brain vascular
endothelial and A549 human type 2 pneumocyte cell lines
(Fig. 3E). Thus, high PAFR and LR expression on vascular
endothelial cells coupled with low expression on cardiomyocytes is
a potential explanation for why the pneumococcus could
translocate into the myocardium, yet the bulk of these bacteria
were found to be extracellular in cardiac tissue.

Antibodies against CbpA and pneumolysin protect mice
against lesion formation
Given the presumptive critical roles for CbpA and pneumolysin
in cardiac microlesion formation, we subsequently tested whether
antibodies against these proteins, derived by immunization of mice
with individual and fused protein constructs, afforded protection
against cardiac damage. More specifically, we tested the
pneumolysin toxoid L460D [26], recombinant R1 domain of
CbpA that contains the LR and polymeric immunoglobulin
receptor binding domains of CbpA (CbpA-R12) [27], and
constructs of L460D containing fused peptides from CbpA
corresponding to the LR (i.e. NEEK) and the polymeric
immunoglobulin receptor (i.e. YPT) binding motifs (Fig. 5A)
[28]. In humans, the YPT motif of CbpA binds to polymeric
immunoglobulin receptor in the nasopharynx [29]. We included
the constructs containing the YPT motif as a way to discern if
antibodies against CbpA, but not to the LR binding domain, were
sufficient to prevent microlesion formation. All mice immunized
with these constructs developed high antibody titers to pneumolysin, CbpA, or both, as expected based on their immunogen
composition (Fig. S4A). In this instance, to avoid early clearance
due to pre-existing antibody, a higher bacterial challenge
(105 CFU) was used to ensure high and equivalent bacterial titers
in the blood during the first 24 h (Fig. S4B). Mice immunized
with CbpA-R12, L460D, and YPT-L460D did not reach statistical
significance versus the alum control. In contrast, mice immunized
with the L460D constructs bearing the NEEK domain, L460DNEEK or YLN, had significantly reduced microlesion formation
versus the alum control (Fig. 5B).

Cardiomyocytes undergo cell death following exposure
to pneumolysin
TUNEL staining indicated the presence of dead or dying
cardiomyocytes during early microlesion formation and at the
leading edge of mature lesions (Fig. 4A). Pneumolysin, the S.
pneumoniae pore-forming toxin, was localized at the microlesion
site using immunofluorescent microscopy (Fig. 4B) as was
pneumococcal cell wall (Fig. 4C), the latter which we have
previously shown inhibits cardiac contractility [10]. In vitro studies
with A549, RBCEC6 and HL-1 cells indicated that pneumococcal
attachment and invasion alone did not contribute in a meaningful
fashion to host cell death (Fig. S3). Yet, in vitro HL-1
cardiomyocytes were susceptible to killing with recombinant
pneumolysin (Fig. 4D), but not with purified cell wall (Fig. 4E).
Mice infected with a pneumolysin deficient mutant developed
significantly fewer and much smaller lesions than the control
(Fig. 3A). Similar to the CbpA mutant, the pneumolysin mutant
did not replicate in the blood to the same levels as wild type. Thus,
leaving open the possibility that the absence of microlesions was
instead due to the decreased bacterial burden. Retro-orbital
injection of mice with a bolus of recombinant pneumolysin (n = 2),
purified pneumococcal cell wall (n = 2), or both together (n = 7),
failed to cause microlesion formation after 24 h despite considerable signs of damage and inflammation within the cardiac
vasculature such as the sloughing of vascular endothelial cells
and the presence of adherent leukocytes.
Pneumolysin triggers activation of the NLRP-3 inflammasome
[23], which in turn results in the secretion of active IL-1b and in
some instances death by pyroptosis [24]. In the lungs and central
nervous system, pneumolysin induced IL-1b and cell death have
been shown to contribute to the inflamed tissue state and the
recruitment of immune cells during pneumococcal infection
[23,25]. Consistent with the absence of immune cell infiltration
at cardiac microlesion sites, immunohistochemistry for IL-1b was
negative at the lesion sites and IL-1b was not detected in the
supernatant of HL-1 cardiomyocytes exposed to pneumolysin
(n = 4) or HL-1 cells infected with live bacteria (n = 4) after 2, 4
and 8 h. Likewise, mice deficient in caspase-1 formed lesions
similar in morphology at 30 h to those of wildtype mice, albeit .3fold more frequently in number (WT n = 6, 9.7562.5 microlesions/section; Caspase-1 KO n = 6, 33.3368.8 microlesions/
section; P = 0.026). This may have been due to greater level of
bacteremia experienced by the IL-1b deficient mice (WT n = 13,
2.47610864.366107 CFU/mL blood; Caspase-1 KO n = 6,
7.82610863.186108 CFU/mL blood; P = 0.012).
PLOS Pathogens | www.plospathogens.org

Cardiac microlesion sites are characterized by immune
cell infiltration and collagen deposition during the
convalescent stage
We sought to determine how cardiac microlesions resolved
following successful antimicrobial therapy. To do this we examined
hearts from mice rescued from death with high-dose ampicillin begun
at 30 h post-infection. In these mice, blood samples were culture
negative 12 h after ampicillin was begun, yet the survival rate was
31.7% (n = 41). In sharp contrast to the lesions before treatment,
robust immune cell infiltration at distinct focal sites distributed
throughout the myocardium was now observed at day 3, 42 h
following the start of antimicrobial therapy, and this persisted through
day 7 (Fig. 6A). At day 3, the vacuolation characteristic of the
microlesions remained discernible in some instances, although visible
pneumococci were now completely absent. Based on morphological
criteria, immune cells at microlesion sites appeared to be a mixed
population of neutrophils and macrophages. Following antibiotic
therapy, cardiac inflammation persisted through day 7 with the
appearance of collagen in resolving lesions (Fig. 6B). These changes
were similar to the scarring and remodeling that is known to occur
after myocardial infarction [30–34].

Discussion
Despite over a century of investigation of IPD-related complications, this is first report to suggest that pneumococcal invasion of
6
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Figure 3. Lesion formation is dependent on the host protein PAFR and the bacterial adhesin CbpA. A) Total counts, size of lesions, and
bacterial burden in BALB/c mice infected with TIGR4 (24 h n = 8; 30 h n = 12), T4 DcbpA (24 h n = 8; 30 h n = 13), and T4 Dpln (24 h n = 8; 30 h n = 15)
post-infection. B) Counts of cardiac lesions and bacterial burden found in sections from TIGR4 infected wild-type C57BL/6 (n = 6, n = 13, respectively)
and PAFR2/2 (n = 9, n = 6, respectively) mice. C) Cardiac lesions and bacterial titers in the blood in TIGR4 infected BALB/c mice following passive
immunization with monoclonal antibodies against LR (anti-LR n = 8) or with an isotype control (n = 8). D) Immunofluorescence microscopy of a
cardiac section treated with FITC conjugated anti-PAFr or anti-LR antibodies in addition to tomato lectin that is selective for vascular endothelial cells.
DAPI was used to stain nuclei. Top left image was taken under bright field with the rectangle indicating the location of cardiac blood vessels. Note
that on overlaid images of the same tissue section PAFR and LR were found primarily on the vascular endothelial cells and not on cardiomyocytes. E)
Comparison of pneumococcal invasion rates into rat HL-1 cardiomyocytes, human type II pneumocytes (A549) and rat brain endothelial (RBCEC6) cell
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lines. The graph represents the ratio of invasive over adherent CFUs (n = 3, each with 4 replicates). Statistical analysis on panels A–C and E was
performed using a non-parametric Mann-Whitney rank sum test; *P,0.05.
doi:10.1371/journal.ppat.1004383.g003

the lung and brain. Importantly, when we observed pericarditis
(Fig. 2B), immune cells were present, suggesting that the absence
of an immune cell response may be specific to cardiomyocytes. Yet
our observation of a purulent-free lesion within the calf of an
infected mouse (Fig. S2) instead suggests that this may instead be
a phenomena shared by striated muscle cells. The immune
response to S. pneumoniae is primarily driven by a TLR-2
response to peptidoglycan in cell wall [35]. TLR-2 is found both in
skeletal and cardiac muscle, and cardiomyocytes have been shown
to respond to S. aureus peptidoglycan [8]. Why the host response
to cardiomyocyte infection by the pneumococcus is distinct from
other tissues or during infection by other pathogens remains

myocardial tissue may occur during IPD. Cardiac microlesion
formation can contribute to cardiac dysfunction by physical
interruption of conduction pathways, cardiomyocyte death due to
pneumolysin, and loss of contractility by the release of cell wall [1].
Cardiac remodeling as a result of collagen deposition is also a
viable explanation for the increased mortality rates that are seen in
convalescent individuals who have experienced pneumococcal
CAP for up to one-year post-infection [4].
S. pneumoniae cardiac microlesions were highly distinct from
typical Gram-positive abscesses in that they lacked the profuse
infiltration of immune cells [19]. They were also distinct from
purulent exudate that characterizes pneumococcal infections of

Figure 4. Effect of pneumolysin on cardiomyocyte viability. A) Immunofluorescent TUNEL (red) staining of cardiac microlesions from BALB/c
mice 30 h following intraperitoneal infection. Pneumococci were detected using antibodies against serotype 4 capsular polysaccharide (green) and
cardiomyocyte nuclei stained with DAPI. B) Detection of pneumolysin (red) in a microlesion using anti-pneumolysin monoclonal antibody. C)
Detection of pneumococcal cell wall (red) in microlesions by immunohistochemistry using TEPC-15 an IgA monoclonal antibody against cell wall. For
panels A–C) fluorescent microscopy using the corresponding control antibody is shown immediately below. Dashed line demarcates the site of the
lesion. Vybrant MTT Cell Proliferation Assay was used to determine cell viability of HL-1, A549, and RBCEC6 cells following their exposure to D)
recombinant pneumolysin (rPLY) or E) purified pneumococcal cell wall. Experiments were done 3 times each with 4 replicates. Shown are the results
from single, representative experiments.
doi:10.1371/journal.ppat.1004383.g004
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Figure 5. YLN immunized mice are protected against lesion formation. A) Top left: Schematic representation of the anti-parallel helices of R
domains of CbpA. Square: binding site for polymeric immunoglobulin receptor showing amino acids at the turn (i.e. YPT); Circle: binding site for LR
showing amino acids at the turn (i.e. NEEK). Top right: Schematic representation of various fusion protein derivatives of CbpA and the pneumolysin
toxoid L460D used for vaccination. YLN is identified as composed of YPT-L460D-NEEK in our studies. B) Cardiac lesion number per individual mouse
(circle) at 30 h post infection obtained from immunized mice. Experimental cohort size: Alum = 20; CbpA-R12 = 19; L460D = 10; YPT-L460D = 10;
L460D-NEEK = 10; YLN = 20. Asterisks denote a statistical significant difference versus the alum control. Statistical analysis was done using KruskallWallis a One-way ANOVA on Ranks.
doi:10.1371/journal.ppat.1004383.g005

unclear. We postulate that the impaired host response to S.
pneumoniae is, in some fashion, tied to the maintenance of vital
cardiac function, but also involves specific host-pathogen interactions that are restricted to the pneumococcus.
Microlesion formation was dependent on CbpA/LR and
ChoP/PAFR interactions. These are the same interactions that
have been implicated in translocation across the cerebral
vascular endothelium during the development of pneumococcal meningitis [12,13]. Most respiratory tract pathogens,
including Haemophilus influenzae and Neisseria meningitidis,
also target LR and PAFR for epithelial and endothelial cell
interactions and as such may also be capable of translocation
into the myocardium. We have previously shown that statin
therapy protects sickle cell mice against fulminate S. pneumoniae infection by down-regulating PAFR on endothelial cells
and inhibiting the pore-forming activity of pneumolysin [36].
A similar protective effect for statins against cardiac lesion
formation during IPD is supported by the fact that individuals
on statin therapy who were hospitalized for pneumonia have
significantly better post-hospital discharge survival rates than
PLOS Pathogens | www.plospathogens.org

controls [37]; albeit direct evidence that statins impair
pneumococcal translocation into the myocardium is lacking.
Importantly, the pathophysiology described here is independent of the development of the sepsis syndrome. Microlesions
were detected before the onset of sepsis in our experimental
model (i.e. 24 h) and this presumably required bacterial
translocation into the heart at an even earlier time point.
The correlation of lesion formation with duration and intensity
of bacteremia, which provides the bacteria with sufficient
opportunity to invade the heart, is consistent with what is
known regarding the development of meningitis. High-grade
persistent bacteremia without translocation of bacteria was
insufficient for the development of cardiac microlesions, as
evidenced by the absence of lesions in PAFR KO mice and in
wildtype mice treated with monoclonal antibodies against LR,
both of which had equivalent levels of bacteremia as their
respective controls with microlesions. In contrast, high-grade
bacteremia when sufficiently prolonged in mice expressing LR
and PAFR led to more frequent and larger lesion formation, as
evidenced in the Caspase-1 deficient mice. For mice infected
9
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Figure 6. Immune cell infiltration and collagen deposition following antimicrobial therapy. BALB/c mice were infected with S.
pneumoniae and beginning at 30 h treated with ampicillin for rescue. A) Representative H&E stained cross sections of hearts from BALB/c mouse at
time when ampicillin treatment was initiated as well as 3 and 7 days post-infection. Note that former microlesion sites are now characterized by
robust immune cell infiltration. B) Heart sections were also stained with Picrosirius Red to visualize collagen deposition.
doi:10.1371/journal.ppat.1004383.g006
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nent scarring. This would most likely exacerbate pre-existing
cardiac related problems. Research is merited to determine the
true frequency of cardiac microlesions in patients hospitalized with
IPD, if modifications in antibiotic therapy improve long-term
outcomes, and if prevention of cardiac damage is an indication for
vaccination.

with D39, the duration of survival following challenge was
most likely insufficient.
Exposure of cardiomyocytes to purified pneumolysin or live S.
pneumoniae was not associated with release of IL-1b despite the
fact that pneumolysin could trigger cell death. The lack of IL-1b
indicated cardiomyocyte death was not the result of pyroptosis.
Necrotic cell death, such as that caused by membrane lysis,
typically elicits a strong inflammatory response due to the release
of damage-associated molecular pattern molecules (DAMPs).
Along similar lines, necroptosis, a cell-programmed mode of
necrosis, has been shown to be involved in ischemia-reperfusion
injury of the heart and to be highly inflammatory [38] and Grampositive pore-forming toxins other than pneumolysin have been
implicated as inducers of necroptosis [39,40]. Yet during acute
pneumococcal cardiac microlesion formation, inflammation was
decidedly absent. This suggests that instead, pneumolysin triggers
immune quiescent apoptosis [41]. Importantly, robust immune
cell infiltration was detected at microlesion sites only following
antimicrobial therapy. How or why the cardiomyocyte response
differs between live versus killed S. pneumoniae is unclear. Further
studies are required to begin to answer this important question.
Our observation of profuse immune cell infiltration accompanied by collagen deposition after antibiotic therapy, is suggestive
that bacterial death after microlesion formation results in cardiac
remodeling similar to what is seen following infarction. Such scars
have been shown to result in permanent changes in cardiac
electrophysiology and function [30–34]. Importantly, it is not clear
if the class of antimicrobials used to treat IPD would have an
impact on cardiac function or the size of the affected region during
convalescence. Treatment with cell wall acting antimicrobials,
such as ampicillin, results in the lysis of S. pneumoniae and this
would enhance the release of pneumolysin and cell wall from
previously intact pneumococci. In contrast, treatment with
antimicrobials that do not result in bacterial lysis, such as
macrolides, would presumably limit tissue damage and potentially
could improve cardiac outcomes. Along such lines, a reduction in
cardiac scarring would also presumably lower the risk for mortality
in convalescent individuals. Importantly, immunization of mice
with a fusion protein composed of the LR binding domain of
CbpA and the pneumolysin toxoid L460D conferred significant
protection against microlesion formation. This result supports the
critical role for these virulence determinants in microlesion
formation and suggests that this form of cardiac damage is
potentially vaccine preventable.
Based on our current data, we propose the following model for
cardiac microlesion development. During severe invasive disease,
pneumococci in the bloodstream engage host LR and PAFR with
surface adhesin CbpA and cell wall ChoP residues, respectively. As
a result bacteria are translocated into the myocardium. Due to the
relative absence of LR and PAFr on cardiomyocytes, the bacteria
remain predominantly extracellular, but during replication they
release toxic products such as pneumolysin that kill cardiomyocytes and cell wall that inhibits contractility. For as yet unknown
reasons, this does not result in the recruitment of immune cells,
allowing for further replication of the bacteria and growth of the
microlesions. Ultimately, this culminates in altered electrophysiological conductance or contractility that serves as a substrate for
acute cardiac events. As such, we propose that during infection
microlesion-mediated cardiac damage, increased myocardial
demand during infection, ventilation-perfusion mismatch, and
the effects of circulating pro-inflammatory factors, together lead
towards an adverse outcome in those with IPD. In convalescent
animals, profuse immune cell recruitment to the microlesion site
occurs accompanied by collagen deposition and possibly permaPLOS Pathogens | www.plospathogens.org

Materials and Methods
Ethics statement
All mouse experiments were reviewed and approved by the
Institutional Animal Care and Use Committees at The University
of Texas Health Science Center at San Antonio (protocol
#13032-34-01C) and St. Jude Children’s Research Hospital
(protocol #250). Animal care and experimental protocols adhered
to Public Law 89-544 (Animal Welfare Act) and its amendments,
Public Health Services guidelines, and the Guide for the Care and
Use of Laboratory Animals (U.S. Department of Health & Human
Services). Cardiac sections from rhesus macaques were obtained
with permission and were remnant from completed and independent investigations performed at Tulane National Primate
Research Center [20]. Cardiac sections from individuals who
succumbed to IPD were collected during autopsy at Hospital
Universitario de Getafe in Madrid Spain from 2000 to 2010, prior
to the start of this study. Paraffin-embedded cardiac sections were
provided for analysis in a de-identified fashion and work done was
determined not to be human subject research by the Institutional
Review Board at The University of Texas Health Science Center
at San Antonio (protocol #HSC20140389N).

Mice and macaques
BALB/c, C57BL/6, PAFR2/2 [42], Caspase-12/2
(B6N.129S2-Casp1tm1Flv/J) mice of both sexes were either
obtained from The Jackson Laboratory (Bar Harbor, Maine) or
from institutional facilities. All mice were used between 10–12
weeks of age. KO mice and their respective WT controls were
obtained from the same facility and were raised under similar
conditions. Non-human primate studies were conducted on male
rhesus macaques (Macaca mulatta) of Indian origin at 4 to 6 years
of age. All monkeys were infected with SIV Mac251 4 months
prior to S. pneumoniae challenge [20].

Bacterial strains and media
Wild type strains used in this study included S. pneumoniae
serotype 4 strain TIGR4 [43], serotype 2 strain D39 [44], and
serotype 19F strain 6319 (ATCC 6319). Isogenic TIGR4 mutants
lacking CbpA (DcbpA2), and pneumolysin (Dpln2) have been
previously described [45]. To generate purified pneumococcal cell
wall, we used the unencapsulated strain R6 and followed published
protocols [10]. S. pneumoniae was grown in Todd-Hewitt broth or
on blood agar plates at 37uC in 5% CO2. Recombinant
pneumolysin was purified from transformed Escherichia coli and
hemolytic activity measured [46].

Infection and histology
For mouse experiments, exponential phase cultures of S.
pneumoniae were centrifuged, washed with sterile phosphatebuffered saline (PBS), and suspended in PBS at a final
concentration of colony-forming units 16104 CFU/mL. Mice
were anesthetized with 2.5% vaporized isoflurane and injected
intraperitoneally (i.p.) with 100 ml of the S. pneumoniae suspension. Bacterial titers were determined by extrapolation of colony
counts from plated serial dilution of tail bleeds. Once sacrificed,
the heart and/or other organs were harvested, washed in PBS to
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lentum (Vector Laboratories) was used (1:1000). DAPI (49,6Diamidino-2-Phenylindole, Dilactate) at 5 mg/mL was used for
visualization of eukaryotic nuclei. Tissue sections were washed and
mounted with FluorSave (Merck Biosciences). For TUNEL
analysis of cardiac microlesions, the Millipore ApoptagKit Red
In Situ Apoptosis Detection Kit (EMD Millipore Corp.) was used
to detect fragmented DNA. Images were acquired using an
Olympus FV-1000 confocal system, running the Fluoview 3.1
software (Olympus Corporation) at the University of Texas Health
Science Center Optical Imaging Core Facility.

remove excess blood, placed into specimen collection cassettes and
set into 10% formalin solution and subsequently paraffin
embedded. A detailed description of the experimental protocol
used for infection of the rhesus macaques is available [20].
Macaques were administered 26106 CFU of S. pneumoniae strain
6319 in 2 mL saline into a subsegment of the right lower lobe
using a pediatric fiber optic bronchoscope. These studies were
designed to determine the effect of chronic alcohol on lung viral
titers and the host response to pneumococcal lung infection. Heart
tissue came from animals that expired within the first 4 days due to
fulminant bacterial infection or were euthanized after 28 days.
Paraffin embedded cardiac samples were sectioned then stained
with hematoxylin and eosin (H&E) and/or Gram stained by the
University of Texas Health Science Center at San Antonio
Histology and Immunohistochemistry Laboratory. Picrosirius Red
staining was performed for detection of collagen deposition. Tissue
sections were mounted with Permount (Fisher Scientific) mounting
solution.

Transmission electron microscopy
Mouse hearts were excised and placed in phosphate buffered
4% formaldehyde with 1% glutaraldehyde prior to processing.
The hearts were prepared for TEM imaging as previously
described [47]. Images were generated in the UTHSCSA Electron
Microscopy Laboratory using the JEOL 1230 microscope and
AMT digital imaging system.

Antibiotic rescue of septic mice

Cell based assays

Mice were infected with 103 CFU of TIGR4. Beginning at
30 hours post-infection, mice were administered ampicillin
(20 mg/kg body weight) in saline i.p. every 12 hours 3X. Hearts
were collected at designated time points and processed for
histological examination. Blood was collected from the tail vein,
plated, and the plates incubated to confirm bacterial clearance.

HL-1 atrial myocytes (a gift from Dr. W. Claycomb, Louisiana
State University, New Orleans, LA) were maintained in
Claycomb’s medium (JRH Biosciences) supplemented with 10%
FBS (JRH Biosciences), 2 mM L-glutamine (Invitrogen Life
Technologies), and 0.1 mM norepinephrine (Sigma-Aldrich).
Adhesion and invasion assays of A549 lung epithelial cells (ATCC)
and RBCEC6 brain endothelial cells with unencapsulated TIGR4
(T4R) were performed as previously described [42]. Cytotoxicity
after infection with T4R was determined by measuring LDH
(Thermo Scientific) in the cell culture supernatents following a
30 minute incubation for T4R adhesion or a 2 hour incubation
for T4R invasion. One non-infected well per assay was used to
determine eukaryotic cells/well. The graph represents the average
of CFUs that adhered to or invaded each cell. For cell viability
experiments, A549, HL-1 and RBCEC6 cells were seeded in a 96
well plate at 3.56105 cells/mL (200 uL/well) in serum free F12K
media (phenol red free). Cells were grown for 24 h at 37uC 5%
CO2. Recombinant pneumolysin was serial diluted (buffer PBS,
0.1% BSA, 0.15% DTT) 1:2 with a starting concentration of
25 mg/mL. 50 mL diluted rPLY was added to the cells and the
plates were incubated 24 h at 37uC 5% CO2. Vybrant MTT Cell
Proliferation Assay was used to determine cell viability according
to manufacturer’s protocol (Molecular Probes). Absorbance was
read at 540 nm and plotted. Data represent the average of 3
independent experiments with 4 wells per pneumolysin dilution.
For experiments testing cardiomyocytes for necroptosis, HL-1
cardiac cells were infected with the T4R strain of S. pneumoniae at
MOI 0.1, 1, and 10 for 6 hrs+/230 uM Necrostatin-1 (Alfa
Aesar). Cells were stained with Annexin V APC (BD Biosciences)
and Propidium Iodide (BD Biosciences) for flow cytometry (BD
FACSCanto II) and analysis by FlowJo software (TreeStar Inc.).

Electrocardiogram analysis and cardiac troponin assay
Limb-lead ECGs were acquired at 200 kHz using the 100B
electrocardiogram data acquisition system (iWorx) with mice
under 1–2.5% vaporized isoflurane anesthesia in an oxygen mix
on a heated surgical platform (Indus Instruments). At designated
times, infected mice were euthanized and exsanguinated by
cardiac puncture. An aliquot of blood was diluted in saline
containing heparin and used to extrapolate bacterial titers from
colony counts. The remainder of blood was processed for serum
collection. Cardiac troponin in these samples was determined
using the mouse Cardiac Tn-I ELISA kit (Life Diagnostics).

Fluorescent microscopy of tissue sections
Immunofluorescent microscopy was done using both fixed and
frozen cardiac sections. Fixed cardiac sections were deparaffinized
and rehydrated by placing section in xylene, and subsequent
graded ethanol washes. Samples were permeabilized with 10 mM
sodium citrate pH = 6 for 10 min, washed with PBS, and blocked
with 10% fetal bovine serum (FBS) in PBS for 1 h. Frozen sections
on glass slides were fixed in 4% paraformaldehyde, permeabilized
in 0.2% Triton X, blocked with 10% fetal bovine serum (FBS) in
PBS for 1 h. Cardiac sections were subsequently incubated with
either rabbit anti-serotype 4 pneumococcus antiserum (1:1,000)
(Statens Serum Institut), TEPC15 IgA Kappa from murine
myeloma (1:500) (Sigma), rabbit anti-pneumolysin polyclonal
antibody (1:50) (Abcam), anti-laminin receptor monoclonal
antibody (1:200) (Abcam) or anti-PAFR mouse monoclonal
antiobdy (1:500) (Cayman Chemical) antibody, or the respective
isotype control antibody at the corresponding dilution. After
washing with PBS, sections were covered with 10% goat or BSA
containing either goat anti-rabbit FITC conjugated antibody
(1:2,000) (Invitrogen) or donkey anti-rabbit rhodamine conjugated
antibody (1:200) (Millipore). Using the Invitrogen SuperPicTure
Kit, pneumolysin could be visualized. Sections were counterstained with Harris hematoxylin solution (Sigma) and mounted
using Histomount solution (Invitrogen). To visualize vascular
endothelial cells, labeled tomato lectin from Lycopersicon EscuPLOS Pathogens | www.plospathogens.org

Mouse immunization and challenge
BALB/c Mice were primed (day 1) and boosted (days 14 and
28) i.p. with 10 mg protein and 130 mg alum. Serum was obtained
(day 35) and IgG titers against pneumolysin and CbpA were
determined by ELISA. Mice were challenged (day 50) i.p. with
16103 CFU TIGR4. At 24 h post challenge blood was drawn and
plated on blood agar plates to determine degree of bacteremia.
Mice were sacrificed at 30 h post challenge and the hearts were
harvested for histopathology. For some experiments, mice were
injected retro-orbitally with either immunoglobulin-isotype control
or 40 mg of monoclonal antibody against 67-kDa laminin receptor
(Abcam) [48].
12
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invasion. Lysis buffer served as the positive control for 100% cell
toxicity while serum-free media was used as a negative control.
Assay was performed using 4 wells per sample. Results shown are
representative of duplicate experiments.
(PDF)

Statistical analysis
Regression analysis of bacterial titers and troponin levels was
performed using a Pearson correlation coefficient calculator. Pairwise comparisons were performed either using a Student’s t-test or
non-parametric Mann-Whitney rank sum test. For comparisons
between 3 or more cohorts a Kruskal-Wallis One Way ANOVA
on Ranks was used.

Figure S4 A) Antibody response to pneumococcal protein
constructions. Antibody titers to pneumolysin and CbpA in serum
of mice as determined by ELISA following their immunization
with the designated recombinant constructs. Circles represent
values for individual mice. B) Levels of bacteremia following
pneumococcal challenge. Bacterial titers in the blood of these same
mice 24 h after high-dose intraperitoneal injection with 105 CFU
TIGR4. Experimental cohort size: Alum = 20; CbpA-R12 = 20;
L460D = 10; YPT-L460D = 10; L460D-NEEK = 10; YLN = 20.
(PDF)

Supporting Information
Figure S1 ECG tracings from individual mice (M) following
intraperitoneal challenge with S. pneumoniae. Note the onset of
aberrant electrophysiology. Saline challenged controls (C) showed
no disturbances through 48 h despite identical anesthesia
treatment and repeated ECG measurements.
(PDF)
Figure S2 Microlesion lacking immune cell infiltrates and filled
with Streptococcus pneumoniae found in the gastrocnemius muscle
of a mouse 30 h after intraperitoneal challenge.
(PDF)

Author Contributions
Conceived and designed the experiments: AOB BM JSH EMM GJB AE
CJL EIT CJO. Performed the experiments: AOB BM GG JSH JH JG PF
GVH MH KIH SN JAL PC RG CJL. Analyzed the data: AOB BM JSH
MIR MLL MH EIT CJO. Contributed reagents/materials/analysis tools:
JSH GJB AE CJL EIT CJO. Contributed to the writing of the manuscript:
AOB BM EIT CJO.

Figure S3 Cell cytotoxicity following pneumococcal adhesion

and invasion. Cytotoxicity as measured by release of lactose
dehydrogenase in cell culture supernatants following a 30 min
incubation for pneumococcal adhesion or a 2 h incubation for
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